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ABSTRACT
The gut microbiome is not a silent ecosystem but exerts
several physiological and immunological functions. For
many decades, lactobacilli have been used as an
effective therapy for treatment of several pathological
conditions displaying an overall positive safety proﬁle.
This review summarises the mechanisms and clinical
evidence supporting therapeutic efﬁcacy of lactobacilli.
We searched Pubmed/Medline using the keyword
‘Lactobacillus’. Selected papers from 1950 to 2015 were
chosen on the basis of their content. Relevant clinical
and experimental articles that used lactobacilli as
therapeutic agents have been included. Applications of
lactobacilli include kidney support for renal insufﬁciency,
pancreas health, management of metabolic imbalance,
and cancer treatment and prevention. In vitro and
in vivo investigations have shown that prolonged
lactobacilli administration induces qualitative and
quantitative modiﬁcations in the human gastrointestinal
microbial ecosystem with encouraging perspectives in
counteracting pathology-associated physiological and
immunological changes. Few studies have highlighted
the risk of translocation with subsequent sepsis and
bacteraemia following probiotic administration but there
is still a lack of investigations on the dose effect of these
compounds. Great care is thus required in the choice of
the proper Lactobacillus species, their genetic stability
and the translocation risk, mainly related to
inﬂammatory disease-induced gut mucosa enhanced
permeability. Finally, we need to determine the adequate
amount of bacteria to be delivered in order to achieve
the best clinical efﬁcacy decreasing the risk of side
effects.
INTRODUCTION
The impact of the gastrointestinal (GI) tract on
brain functions and behaviour including anxiety,
mood, cognition and pain regulation has been
recognised since the 19th century as Hipocrates’
dictum stated “Let the food be thy medicine and
medicine be thy food”.1 Therefore, the gut-brain
axis has been proposed as a homoeostatic route of
communication using neuronal, hormonal and
immunological pathways.1–3 The GI tract, which is
an active part of this axis, is harboured by approxi-
mately 100 trillion organisms, mainly anaerobes,
which constitute the microbiome and exceed 10
times the overall number of cells present in the
human body.4 5 The microbiome plays a pivotal
role in the development and functionality of the
innate and adaptive immune responses.1 Among
microbiome-composing organisms, lactobacilli can
inhibit the growth of pathogenic bacteria and have
a favourable safety proﬁle.6 However, different
species of the genus Lactobacillus (L.) can produce
different particular responses in the host, and the
effects exerted by some strains of the same species
may not be beneﬁcial.7
AIM AND SEARCHING CRITERIA
In this review, we summarise the experimental and
clinical evidence on lactobacilli by providing a com-
prehensive overview of their efﬁcacy for treatment
of numerous pathologies and outlining new thera-
peutic trends. We searched Pubmed/Medline using
the keyword ‘Lactobacillus’. Selected papers from
1950 to 2015 were chosen on the basis of their
content. Relevant clinical and experimental articles
that used lactobacilli as therapeutic agents and
written in English language have been included.
Clinical ﬁndings organised by pathology are sum-
marised in tables 1–15.
EXPERIMENTAL EVIDENCE
Adhesion to the gastrointestinal mucosa
Dietary changes, antibiotic exposure and infections
may cause dysbiosis, a perturbation of the
microbiome-host symbiosis that favours the inva-
sion and growth of pathogenic species to the detri-
ment of health-promoting bacteria, including
lactobacilli, within the GI tract.8 9 Indeed, lactoba-
cilli adhesion to the host’s GI tract, by means of an
interaction with toll-like receptors, is of crucial
importance due to its ability to trigger the host’s
immune response.10 11 Nevertheless, adhesion to
the GI tract can also be driven by surface proteins
and fatty acids, as observed for L. rhamnosus
PEN,12 and proteinaceous surface layer compo-
nents, as observed for L. plantarum 91.13
Therefore, the ability of lactobacilli to adhere
and colonise the GI tract mucosa has been investi-
gated in the clinical setting and is summarised in
table 1.14–17
Antitumour activity
Intestinal bacteria produce mutagens such as deoxy-
cholic acid from primary bile acids or by enzymatic
conversion when foreign compounds, such as
nitroaromatics, azo compounds and nitrates, are
ingested.18 Lactobacilli are capable of competitively
inhibiting carcinogen and mutagen formation, alter-
ing overall metabolism, adsorbing and removing
toxic and mutagenic metabolites and producing
protective metabolites.19 In the context of colorec-
tal cancer, the prevention mechanism exerted by
probiotics may be a combination of different
actions such as intestinal microbiota modiﬁca-
tion,20–26 inactivation of cancerogenic
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compounds,27–35 competition with putrefactive and pathogenic
microbiota,36–40 improvement of the host’s immune
response,41–55 enhancement of natural killer cell cytotoxicity56
and inhibition of interleukin (IL) 6 production in the colonic
mucosa57 counteracting cancer development by antiproliferative
effects58 via regulation of apoptosis and cell differentiation,59–67
fermentation of undigested food68–73 and inhibition of tyrosine
kinase signalling pathways.74 Experimental studies have also
shown that lactobacilli contained in dietary supplements and fer-
mented food, such as yogurt heat-killed L. casei strain Shirota
(LC 9018)54 reduce colon cancer risk.75–77 These activities have
been ascribed to the alteration of the gut microbiota and, subse-
quently, to the inhibition or the induction of colonic enzymes
controlling the growth of harmful bacteria, improving immune
function and stimulating the production of metabolites posses-
sing antitumour activity. Clinical studies showing efﬁcacy of
lactobacilli for treatment of cancer have been summarised in
table 2.
Antitoxic activity
Lactobacilli display detoxifying properties and their ability to
neutralise toxins81 or toxic compounds82 is important to main-
tain the host’s health. For instance, L. reuteri CRL 1098 and
L. acidophilus CRL 1014 showed the ability to enhance tumour
necrosis factor (TNF)-α response to ochratoxin A, a widespread
mycotoxin from Aspergillus and Penicillium species. This myco-
toxin can contaminate food products83 and induce hepatotox-
icity, nephrotoxicity and immunotoxicity,84 thus increasing
TNF-α production and diminishing toxin-induced apoptosis.83
Individual treatment with L. plantarum 2 017 405,
L. fermentum 353, L. acidophilus DSM 21007 and L. rhamnosus
GG antagonised C. difﬁcile isolated from faecal specimens from
adult patients affected by diarrhoea, as observed by measurement
of the inhibition zone.85 Another L. strain, L. reuteri RC-14,86
produced small signalling molecules able to interfere with a key
regulator of virulence genes, agr. Additionally, L. reuteri RC-14
repressed the expression of toxic shock syndrome toxin-1 in
menstrual toxic shock syndrome induced by Staphylococcus (S.)
aureus strains. Quantitative real-time polymerase chain reaction
(PCR) data revealed that transcription from the toxic shock tst
promoter was strongly inhibited in culture supernatant in pres-
ence of L. reuteri RC-14. Moreover, a transcriptional level alter-
ation of virulence-associated regulators was observed, providing
a unique mechanism by which endogenous or exogenous lactoba-
cilli can attenuate production of virulence factors. This study
highlighted the existence of a crosstalk mechanism between two
distinct bacterial signalling systems, that is, alteration in the tran-
scriptional levels of virulence-associated regulators sarA and
saeRS and transcription inhibition from Ptst, P2 and P3 promo-
ters, providing a potential defensive mechanism against S. aureus
infections. Therefore, administration of well-characterised lacto-
bacilli can be helpful to overcome antibiotic-related complica-
tions, such as antibiotic resistance. Based on 16SrDNA sequences
and non-coding fragments characterisation of different lactoba-
cilli, Fei and coworkers reported a signiﬁcantly high nitrite deg-
radation capacity exerted by L. sp DMDL 9010 after a 24 h
fermentation in the medium.87 Compound degradation activity
of lactobacilli has also been observed for cadmium after high
dietary exposure.88 In this regard, two L. keﬁr strains, CIDCA
8348 and JCM 5818, can remove cadmium cations when cocul-
tured with a human hepatoma cell line, HepG2.89 Particularly,
L. keﬁr JCM 5818 is more efﬁcient in protecting cells from
cadmium toxicity. Therefore, since consumption of harmful
metals is a growing medical issue, the regular administration of
formulations containing the above mentioned strains might be
useful to prevent toxin compound-induced lipid peroxidation
and free radical production.
Vaginal colonisation
Vaginal microbiota is dominated by lactobacilli.90 When the
balance among bacterial species within this environment is
altered, antibacterial defense mechanisms lose their efﬁcacy
leading to pathogenic bacteria proliferation.90 For instance,
reduction in the number of vaginal lactobacilli and their anti-
microbial properties (such as lysostaphin expression in order to
cleave the cell wall of S. aureus thus inhibiting its growth),91
and H2O2 production,
92 cause bacterial vaginosis, the most
common symptomatic microbial imbalance.93 In patients
affected by bacterial vaginosis, lactobacilli are replaced
by Gardnerella vaginalis,92 94 Candida (C.) albicans,95
S. aureus,91 96 Neisseria gonorrhoeae40 or other anaerobic
bacteria. Uncontrolled growth of anaerobic bacteria such as
C. albicans and subsequent vaginal colonisation may lead to
Table 2 Clinical studies showing efficacy of lactobacilli for treatment of cancer
Bacteria Dose Pathology Ref. (Design)
B. lactis Bb12
L. rhamnosus GG
+
Oligofructose enriched inulin (SYN1)
1×1010 CFU (total)
12 g
Colon cancer 39(randomised, double-blind, placebo-controlled study)
L. rhamnosus LC705
P. freudenreichii subsp Shermanii
2–5×1010 CFU (of each) Liver cancer 78(randomised, double-blind, placebo-controlled study)
B. longum
L. acidophilus
E. faecalis
108 CFU/g (0.21 g) (total) Colorectal cancer 79(open study)
B. natto
L. acidophilus
10 mg
30 mg
Colorectal cancer 80(open study)
Table 1 Lactobacilli displaying ability to adhere to the
gastrointestinal tract mucosa
Bacteria Dose Ref. (Design)
L. gasseri SBT2055SR 1011 CFU in 200 mL of milk 14(open study)
L. reuteri DSM 12246
L. rhamnosus 19070–2
L. rhamnosus LGG
1010 CFU (of each) 17(double-blind
cross-over study)
L. acidophilus 821–3 1×1010 CFU 15(open study)
L. rhamnosus 19070–2
L. reuteri DSM 12246
1×1010 CFU (of each) 16(open study)
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vulvovaginal candidiasis,97 which is estimated to occur at least
once during the lifetime of 75% of the female population.98
Vaginal microbial imbalance may also represent an important
risk factor for increased risk of urinary tract infections and preg-
nancy complications, such as endometritis, chorioamnionitis,
preterm birth and intrauterine death.99 Intravaginal colonisation
by bacterial strains with high haemolytic activity and pigment
production [eg, group B streptococci (GBS)] is one of the most
important risk factors for disease development in newborns.100
Therefore, a murine model was proposed in order to determine
if L. reuteri CRL1324 would exert a preventive effect on
vaginal colonisation by Streptococcus (St.) agalactiae NH17.100
Following L. reuteri CRL1324 administration, a reduced leuco-
cyte inﬂux induced by St. agalactiae NH17 and a preventive
effect on its vaginal colonisation were observed prior to
the GBS challenge. Although GBS colonization occurs in up to
50–70% of neonates born from colonized mothers,101 the intro-
duction of new antimicrobial agents, such as L. reuteri
CRL1324, could be considered a valuable and safer alternative
to antibiotics to reduce infections caused by GBS. Clinical
studies of lactobacilli showing efﬁcacy for treatment of vaginal
disorders have been summarised in table 3.
Cholesterol-lowering activity
There is an increasing demand for non-pharmacological therap-
ies to improve cholesterol proﬁle due to the cost and side effects
associated with available pharmacological treatments for
cholesterol-related diseases. Hence great attention has been
given to lactobacilli due to their effectiveness in modulating
lipid metabolism reducing statin requirement (statins inhibit the
enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase that
produces about 70% of the total body cholesterol)110 111 and
serum cholesterol level by means of bile salt hydrolase that has a
direct impact on the host’s bile salt metabolism accounting for
the formation of deconjugated bile acids.112 Furthermore,
cholesterol-reducing properties were also observed for L. oris
HMI118, HMI28, HMI43, HMI68 and HMI74 isolated from
breast milk.113 Although all the tested strains assimilated choles-
terol even in the absence of bile salts, surviving in the acidic
conditions of the intestine and tolerating high bile concentra-
tions, L. oris HMI68 showed the highest cholesterol assimilation
deconjugating sodium glycocholate (the most predominant bile
salt in the human intestine) and sodium taurocholate.
Cholesterol assimilation has also been evaluated as a possible
Table 4 Clinical studies of lactobacilli showing efficacy for
treatment of hypercholesterolaemia
Bacteria Dose Ref. (Design)
L. plantarum
CECT 7527
CECT 7528
CECT 7529
1.2×109 CFU
(total)
118(controlled, randomised, double-blind
study)
L. acidophilus L1 N/A 119(double-blind, placebo-controlled,
cross-over study)
L. reuteri NCIMB
30242
5×109 CFU 120(double-blind, placebo-controlled,
randomised, parallel-arm, multicentre study)
L. acidophilus
B. lactis
N/A 121(single-blind and randomised cross-over
study)
Table 3 Clinical studies of lactobacilli showing efficacy for treatment of vaginal disorders
Bacteria Dose Pathology Ref. (Design)
L. plantarum P17630 >108 CFU Acute vulvovaginal candidiasis 97(retrospective comparative study)
L. rhamnosus GR-1
L. fermentum RC-14
>109 CFU (of each) Potential pathogenic bacteria and
yeast vagina colonisation
102(open study)
Kramegin®
(L. acidophilus, lactic acid
+
Krameria triandra extract)
N/A Abnormal cervical cytology 103(open study)
Ellen AB®
L. gasseri LN40
L. fermentum LN99L. casei subsp rhamnosus LN113
P. acidilactici LN23
+
an inert carrying matrix of maltodextrin and
magnesium stearate
108–10 CFU
108–10 CFU
108–10 CFU
Bacterial vaginosis and vulvovaginal
candidiasis
104(randomised double-blind
placebo-controlled study)
L. fermentum LF10
L. acidophilus LA02
+
Arabinogalactan
+
Fructooligosaccharides
0.4×109 CFU (of each)
340 mg
241 mg
Recurrent vulvovaginal candidiasis 105(clinical study)
L. fermentum LF15
L. plantarum LP01
+
Tara gum
0.4×109 CFU (of each)
50 mg
Bacterial vaginosis 106(pilot study)
Florisia®
(L. brevis (CD2), L. salivarius
subsp salicinius (FV2), L. plantarum (FV9))
109 CFU (total) Bacterial vaginosis 107(randomised, double-blind,
placebo-controlled study)
L. rhamnosus GR-1
L. reuteri RC-14
2.5×109 CFU (of each) Vaginal flora overgrowth 108(randomised, double-blind,
placebo-controlled study)
EcoVag®
(L. gasseri (Lba EB01-DSM 14869) L. Rhamnosus
(Lbp PB01-DSM 14870))
108–9 CFU (of each) Bacterial vaginosis 109(double-blind, randomised,
placebo-controlled study)
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therapeutic approach to reduce the risk for cardiovascular dis-
eases.114 In this regard, Tomaro-Duchesneau and coworkers
investigated the ability of 11 L. strains (L. reuteri NCIMB
11951, 701359, 702655, 701089 and 702656, L. fermentum
NCIMB 5221, 8829, 2797, L. rhamnosus ATCC 53103 GG,
L. acidophilus ATCC 314 and L. plantarum ATCC 14917) to
assimilate cholesterol. While L. plantarum ATCC 14917 was
the best cholesterol assimilator in de Man, Rogosa and Sharpe
broth, L. reuteri NCIMB 701089 assimilated over 67% of chol-
esterol under physiological intestinal conditions. The hypocho-
lesterolaemic effect of all strains, particularly of L. reuteri
NCIMB 701089, was linked to intrinsic bile salt hydrolase
activity, assimilation and incorporation in cellular membranes
and compound production, for example, ferulic acid,115 able to
inhibit the activity of enzymes, including 3-hydroxy-3-
methylglutaryl-coenzyme A reductase.116 More recently,
cholesterol-reducing L. spp. GI6, GI9, GI11 and GI15 were also
isolated from traditionally fermented south Indian koozh and
gherkin (a variety of cucumber).117 L. GI9 was able to survive
at pH 2.0 and 0.50% bile salt for 3 h without losing its viability
also exhibiting the maximum cholesterol reduction.
Nevertheless, all tested lactobacilli exhibited inhibitory activity
against several pathogens including Escherichia coli MTCC
1089, Pseudomonas (P.) aeruginosa MTCC 2642, S. aureus
MTCC 7443, Klebsiella (K.) pneumoniae MTCC 7028, Bacillus
subtilis MTCC 8561 and C. albicans BS3 and were able to
deconjugate bile salts. Clinical studies of lactobacilli showing
efﬁcacy for treatment of hypercholesterolaemia have been sum-
marised in table 4.
Antioxidant activity
Lactobacilli can prevent lipid peroxidation122 and free oxygen
radical production123 due to their ability to create the low
oxidation-reduction potential required for their optimal
growth.124 Amaretti and coworkers combined the strains
Biﬁdobacterium (B.) animalis subsp lactis DSMZ 23032,
L. acidophilus DSMZ 23033 and L. brevis DSMZ 23034 and
administered them for 18 days to rats previously treated with
doxorubicin, an anthracycline antibiotic.125 Analysis of plasma
antioxidant activity, glutathione concentration, as well as levels
of reactive oxygen species, revealed a reduction in
doxorubicin-induced oxidative stress, thus supporting antioxi-
dant activity of these probiotics.
Antibacterial and antiviral activity
Probiotic strains beneﬁcially affect the host by replacing patho-
genic bacteria in the GI tract and modulating immune
responses.126 Experimental studies have shown that lactobacilli,
which can adhere to the enterocytes, are effective in preventing
the enteropathogen-mediated infection by competing for nutri-
ents127 and binding sites (eg,inducing intestinal mucin gene
expression),128–132 by secreting antimicrobial substances133 such
as organic acids,134–142 bacteriocins143–145 and hydrogen perox-
ide146–152 and eventually by counteracting the spread within the
colonised body,153–155 reducing gut pH133 141 156 and producing
Table 5 Clinical trials of lactobacilli showing inhibitory activity against H. pylori infection
Bacteria Dose Pathology Ref. (Design)
L. johnsonii La1 > 107 CFU/mL in 80 mL Asymptomatic H. pylori infection 173(double-blind, randomised, controlled clinical study)
L. gasseri OLL2716 1–1.4×107 CFU/g in 90 g H. pylori infection 174(open study)
Enterolactis®
(L. casei subsp casei DG, Vitamin B1,
B2 and B6)
1.6×109 CFU (total) H. pylori infection 182(open study)
Actimel®:
(L. casei DN-114 001)
1×1010 CFU in 100 mL H. pylori infection 183(multicentre, prospective, randomised, double-blind
controlled study)
AB yogurt
(L. acidophilus,
B. lactis,
L. bulgaricus,
St. thermophilus)
5×109 CFU/200 mL (total) H. pylori infection 184(open study)
L. reuteri ATCC 55730 1×108 CFU H. pylori infection 185(open study)
Will yogurt
(L. acidophilus HY2177
L. casei HY2743
B. longum HY8001
St. thermophilus B-1)
≥1×105 CFU
≥1×105 CFU
≥1×106 CFU
≥1×108 CFU
H. pylori infection 186(randomised triple-therapy study)
AB-yogurt
(L. acidophilus La5,
B. lactis Bb12)
107 CFU/mL in 230 mL (of
each)
H. pylori infection 175(open study)
Genefilus F19©
(L. paracasei sub. paracasei F19)
12×109 CFU/2.5 g H. pylori infection-related
gastroesophageal reflux
177(randomised, double-blind, placebo-controlled
study)
L. reuteri Gastrus
(L. reuteri DSM 17938
L. reuteri ATCC PTA 6475)
1×108 CFU (total) H. pylori infection 187(prospective, double-blind, randomised,
placebo-controlled study)
L. gasseri OLL2716 ≥109 CFU H. pylori infection 188(randomised, controlled clinical study)
L. brevis CD2 20×109 CFU H. pylori infection 189(open study)
Table 6 Clinical studies of lactobacilli showing efficacy for
treatment of kidney-related diseases
Bacteria Dose Ref. (Design)
L. acidophilus,
L. plantarum,
St. thermophilus,
B. infantis
L. brevis (CD2)
8×1011 CFU (of each) 197(open study)
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biosurfactants.157–159 As far as bacterial activity is concerned,
L. plantarum GK81, L. acidophilus GK20 and L. plantarum
JSA22 inhibit Salmonella spp infection in intestinal epithelial
cells160 161 and L. acidophilus strain inhibits various pathogenic
bacteria including P. aeruginosa, E. coli, Enterobacter and
K. spp.150 With reference to antiviral activity, lactobacilli harbour
surface layer proteins involved in the enhancement of viral
entry.162 Moreover, increasing data indicate that abnormal
vaginal ﬂora lacking lactobacilli can facilitate viral sexually trans-
mitted disease diffusion such as in the case of HIV,163 human
papilloma virus164 and herpes simplex virus 2.165 In this context,
lactobacilli can exert an important role protecting the vaginal
environment and reducing the risk of virus transmission.
Helicobacter pylori infection
Helicobacter (H.) pylori, a gram-negative microaerophilic
human gastric pathogen, is the main cause of chronic gastritis,
gastric cancer and peptic ulcer disease.166 Antibiotic treatment
for H. pylori infection is associated with serious side effects and
therefore there is an increasing demand for new treatments.
Lactobacilli167 168 have been extensively investigated for treat-
ment of H. pylori infections. Numerous L. strains, that is,
L. gasseri Chen, L. plantarum 18,167 L. gasseri OLL2716,168
L. reuteri,169 L. rhamnosus GG, L. rhamnosus Lc705,
Propionibacterium (P.) freudenreichii subsp shermanii Js,170
L. delbrueckii subsp bulgaricus 48, 144 and GB,171
L. rhamnosus LC705, P. freudenreichii ssp shermanii JS,168
L. acidophilus LB,172 L. plantarum MLBPL1, L. rhamnosus GG
and L. lactis137 possess a neutralising activity against H. pylori.
The same activity was also observed for heat-killed L. johnsonii
Lal and L. helveticus173 as well as for L. gasseri OLL2716,174 as
measured by 13C-urea breath test. The suppressive effect of
lactobacilli on H. pylori infection in vivo and in vitro has been
reviewed.175–177 For instance, L. johnsonii 1088 suppressed
gastric acid secretion in mice via decreasing the number of
gastrin-positive cells in the stomach.176 This result can be con-
sidered a valid add-on therapy during the gold standard treat-
ment for H. pylori eradication by use of a proton pump
inhibitor (PPI), amoxicillin and clarithromycin, and for prophy-
laxis of gastroesophageal reﬂux disease following H. pylori
eradication. Nevertheless, the use of a PPI can also modify the
gut microbiota causing dysbiosis.178–180 In this regard, adding
L. paracasei subsp paracasei F19 to triple therapy is a promising
combination to counteract the effects of PPIs on intestinal dys-
biosis.181 Clinical studies of lactobacilli showing inhibitory activ-
ity against H. pylori infection have been summarised in table 5.
Kidney disease
The last stage of chronic kidney disease induces an increase in
plasma concentration of uraemic wastes and requires kidney
transplantation or chronic dialysis.190 Many studies support the
probiotic approach as an alternative therapy for management of
end-stage renal disease191 and to relieve the ‘uraemic’ condi-
tion.189 192–194 In particular, a high urease activity was observed
for S. spp, L. casei, K. aerogenes and Enterococcus faecium in
the sheep rumen.192 At the same time, the ability to degrade
biogenic amines (BAs) was also assessed by Capozzi and cowor-
kers.193 They isolated two lactobacilli (L. plantarum NDT 09
and L. plantarum NDT 16) from wine and found that they
were able to degrade tyramine (22.12%) and putrescine
(31.09%), respectively. L. casei 4a and 5b, isolated from
Zamorano cheese, also inhibited tyramine along with histamine,
another BA.194 However, BA degradation is not the only mech-
anism under investigation for treatment of end-stage renal
disease and uraemic condition. The ability to degrade oxalate
and to survive within the GI tract of a range of B. and L.
species, isolated from the canine and feline GI tract, has also
been evaluated. In vitro oxalate degradation was detected for 11
Table 8 Clinical studies of lactobacilli showing immunomodulatory activity in various pathologies
Bacteria Dose Pathology Ref. (Design)
L. salivarius LS01
B. breve BR03
+
maltodextrin
1×109 CFU (of each) Moderate/severe atopic dermatitis 223(randomised double-blinded active treatment vs placebo study)
proBiotik
(B. bifidum, L. acidophilus,
L. casei and L. salivarius)
2×109 CFU (total) Atopic dermatitis 207(double-blind, randomised, placebo-controlled study)
L. pentosus b240 2×1010 CFU Common cold 224(randomised, double-blind, placebo-controlled study)
Yakult®
(L. casei Shirota)
6.5×109 CFU in 65 mL Allergic rhinitis 210(double-blind, placebo-controlled study)
L. paracasei -33 2×109 CFU in 200 mL milk Allergic rhinitis 216(randomised, double-blind, placebo-controlled study)
L. acidophilus L-92 N/A Atopic dermatitis 225(double-blind, randomised, clinical study)
Table 7 Clinical studies of lactobacilli showing efficacy for treatment of mastitis
Bacteria Dose Pathology Ref. (Design)
L. fermentum CECT5716
L. salivarius CECT5713
1×109 CFU/200 mg (of each) Infectious mastitis
induced by S. epidermidis or S. aureus
202(open study)
L. salivarius CECT5713
L. gasseri CECT5714
+
a matrix
of methylcellulose
1×1010 CFU/200 mg (of each) Mastitis induced by
S. epidermidis or S. aureus
203(open study)
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out of 18 L. strains (8 L. animalis and 3 L. murinus), but not
for any of the B. strains.195 Rats were fed on four selected
strains (L. animalis 223C, L. murinus 1222, L. animalis 5323
and L. murinus 3133) for 4 weeks; urinary oxalate levels were
signiﬁcantly reduced only in those rats fed on L. animalis 5323
and L. animalis 223C. Oxalate-degrading activity has also been
assessed for other lactobacilli.196 L. paracasei LPC09 displayed
the highest oxalate-degrading activity converting 68.5% of
ammonium oxalate followed by L. gasseri LGS01 (68.4%),
L. gasseri LGS02 (66.2%), L. acidophilus LA07 (54.2%) and
L. acidophilus LA02 (51.3%). The use of lactobacilli as agents
able to integrate into the host’s gut microbiota may thus be con-
sidered helpful in reducing oxaluria and preventing or decreas-
ing the incidence and severity of kidney stone formation.
Clinical studies of lactobacilli showing efﬁcacy for treatment of
urinary stones have been summarised in table 6.
Mastitis
Mastitis is an infectious inﬂammation of one or more breast
lobules198 with S. aureus and S. epidermidis being the most fre-
quent aetiological agents199 and with a prevalence of 3–33%
among breastfeeding mothers.200 Multidrug resistance and bioﬁlm
formation by pathogenic bacteria account for the lack of efﬁcacy
of antibiotics used for treatment of mastitis.201 In this context,
new strategies based on probiotics, as alternatives or complements
to antibiotic therapy for the management of mastitis, are gaining a
prominent role. Clinical studies of lactobacilli showing efﬁcacy for
treatment of mastitis have been summarised in table 7.
Immunomodulatory activity
Lactobacilli are potential adjuvants triggering mucosal and sys-
temic immune responses.204 The immunomodulatory effects of
lactobacilli observed in various physiological systems include
increased natural killer cell cytotoxicity205 206 and induction of
interferon-γ production205–213 and cytokine expression.205–210
212–216 In order to exert these immunomodulatory effects, lacto-
bacilli must resist to digestive system processes217 and adhere to
the host’s intestinal epithelium.218 Lactobacilli (in particular
L. acidophilus) can also be administered together with biﬁdobac-
teria in order to enhance the immune system.219 220 This effect
is accomplished by enhancing systemic/local immunity221 and
concurrently attenuating systemic stress response.222 Clinical
studies of lactobacilli showing immunomodulatory activity in
various pathologies have been summarised in table 8.
Table 9 Clinical studies of lactobacilli showing efficacy for treatment of gastrointestinal pathologies
Bacteria Dose Pathology Ref. (Design)
VSL#3®
(L. casei,
L. plantarum,
L. acidophilus,
L. delbrueckii subsp bulgaricus,
B. longum,
B. breve,
B. infantis
St. thermophilus)
5×1011 CFU/g in 3 g (total) Chronic pouchitis 230(open study)
Yakult®
(L. casei Shirota)
6.5×109 CFU in 65 mL Constipation 231(open study)
Lb. plantarum SN13T 2×108 CFU Constipation 232(double-blind, randomised study)
VSL#3®
(L. casei,
L. plantarum,
L. acidophilus,
L. delbrueckii subsp bulgaricus,
B. longum,
B. breve,
B. infantis,
St. thermophilus)
5×1011 CFU/g in 3 g (total) Ulcerative colitis 233(open study)
Table 10 Clinical studies of lactobacilli showing ability to survive in the gastrointestinal tract
Bacteria Dose Site Ref. (Design)
L. acidophilus 821–3 1×1010 CFU Gastrointestinal tract 15(open study)
L. acidophilus
B. sp
1×108 CFU/g
1×107 CFU/g
in 100 g fermented milk
Small intestine 237(open study)
L. casei shirota 1×108 CFU/mL in 100 mL Gastrointestinal tract 238(14-day baseline, ingestion and follow-up periods)
L. acidophilus LA02 (DSM 21717),
L. rhamnosus LR04 (DSM 16605),
L. rhamnosus GG, (ATCC 53103),
L. rhamnosus LR06 (DSM 21981),
B. lactis BS01 (LMG P-21384)
5×109 CFU (of each) Gastrointestinal tract 239(double-blind, randomised, cross-over study)
L. plantarum LP01 (LMG P-21021)
B. breve BR03 (DSM 16604)
1×109 CFU (of each) Gastrointestinal tract 240(double-blind, randomised, cross-over study)
Lakcid® L
(L. rhamnosus 573/1, 573 L/2 and 573L3)
1.2×1010 CFU in 2 mL 10% glucose Gastrointestinal tract 241(prospective, double-blinded, placebo-controlled
randomised study)
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Table 12 Clinical studies of lactobacilli showing efficacy for treatment of periodontal disease
Bacteria Dose Pathology Ref. (Design)
L. salivarius WB21
+
Xylitol
6.7×108 CFU
280 mg
Severe periodontitis treatment 274(randomised clinical study)
L. reuteri ATCC 55730,
L. reuteri ATCC PTA 5289
1×108 CFU/gum (of each) Gingival inflammation 275(double-blind placebo-controlled study)
Table 11 Clinical studies of lactobacilli showing efficacy for treatment of diarrhoea
Bacteria Dose Pathology Ref. (Design)
Actimel®
(L. casei DN 114001)
1010 CFU/100 mL Antibiotic-associated diarrhoea 249(observational study)
Balance
(L. casei,
L. rhamnosus,
L. acidophilus,
L. bulgaricus,
B. strains
B. breve,
B. longum,
St. thermophilus)
1×108 CFU (total) H. pylori infection-associated diarrhoea 250(randomised placebo-controlled triple-blind study)
L. acidophilus
L.rhamnosus
B. bifidum,
B. longum,
E. faecium
+
fructo-oligosaccharide
2.5×109 CFU (total)
625 mg
Acute diarrhoea 251(prospective randomised, multicentre single-blinded
clinical study)
L. acidophilus CUL60 (NCIMB
30157),
CUL21 (NCIMB 30156),
B. bifidum; CUL20, NCIMB 30153),
B. lactis (CUL34, NCIMB 30172)
6×1010 CFU (total) Antibiotic-associated diarrhoea 252(prospective, parallel group study)
Probiotical
(S. thermophilus,
L. rhamnosus,
L. acidophilus,
B. lactis,
B. infantis
+
Fructooligosaccharides
+
Ascorbic ac
6.5×109 CFU (60 mg)
6.5×109 CFU (28 mg)
6.5×109 CFU (28 mg)
6.5×109 CFU (20 mg)
6.5×109 CFU (20 mg)
20 mg
1.2 mg
Acute gastroenteritis 253(randomised, prospective placebo-controlled parallel
clinical study)
NAN 1®
(L. acidophilus,
L. rhamnosus,
B. longum
S. boulardii)
6.625×107 CFU
3.625×107 CFU
8.75×106 CFU
1.375×107 CFU
Acute rotavirus diarrhoea 254(prospective, double-blind, randomised study)
L. rhamnosus 35 6×108 CFU Acute rotaviral gastroenteritis 255(open-label randomised study)
L. rhamnosus (strains E/N,
Oxy and Pen)
2×1010 CFU (of each) Antibiotic-associated diarrhoea 256(double-blind, randomised, placebo-controlled study)
L. acidophilus LB
+
spent culture medium
109 CFU
160 mg
Non-rotavirus diarrhoea 257(randomised, double-blind, placebo-controlled clinical
study)
Lakcid® L
(L. rhamnosus (573 L/1;
573 L/2;
573 L/3))
1.2×1010 CFU (total) Infectious diarrhoea 258(randomised, double-blind, placebo-controlled study)
L. paracasei ST11 1010 CFU Non-rotavirus diarrhoea 259(randomised, double-blind, placebo-controlled clinical
study)
L. casei CERELA,
L. acidophilus CERELA,
S. boulardii
1011 CFU/g in 175 g (of
each)
Persistent diarrhoea 260(double-blind study)
L. rhamnosus 19070–2
L. reuteri DSM 12246
1010 CFU (of each) Acute diarrhoea 261(randomised placebo-controlled study)
L. casei CERELA,
L. acidophillus CERELA
N/A Bacterial overgrowth-related chronic
diarrhoea
262(randomised, double-blind study)
L. reuteri 1010–11 CFU/g in 1 g Acute diarrhoea 263(randomised, placebo-controlled study)
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Gastrointestinal pathologies
Even if the pathogenesis of irritable bowel syndrome (IBD)
remains unknown, the luminal microbiome plays a key role in
triggering and maintaining a balanced environment within the
GI tract.226 Dysbiosis may also play a key role in IBD.227
Evidence from animal models228 and clinical observations229
outlined the putative therapeutic role of probiotic strains for
IBD treatment. Restoring microbiota-host symbiosis can repre-
sent a promising approach for treatment of the above men-
tioned conditions and can be applied to other GI pathologies, as
summarised in table 9.
Gastrointestinal tract survival
Strains belonging to L. and B. genera are the most studied in
clinical practice.234 The number of bacterial strains that reach
the gut mucosa and colon, depends on several factors such as
strain used, gastric transit survival,15 235 and acid and bile toler-
ance.236 Clinical studies of lactobacilli showing ability to survive
in the GI tract have been summarised in table 10.
Diarrhoea
Imbalance in the gut ﬂora can cause diarrhoea, enteritis and
colitis, among other diseases. VSL#3 (St. thermophilus,
B. breve, B. longum, B. infantis, L. acidophilus, L. plantarum,
L. casei and L. bulgaricus) and L. casei DN-114 001 adminis-
tration decreased the incidence and frequency of radiation
therapy-induced diarrhoea.242 Diarrhoea is also frequent
during antibiotic therapy causing gut ﬂora imbalance.243 244
Clostridium (C.) difﬁcile infection, a gram positive, spore-
forming anaerobe, can cause antibiotic-associated diarrhoea
and colitis in humans.245 246 Boonma and coworkers investi-
gated the probiotic effect of L. rhamnosus L34 and L. casei
L39, two vancomycin-resistant lactobacilli, on the suppression
of IL-8 production in response to C. difﬁcile infection.247
While L. casei L39 suppressed the activation of phosphonuc-
lear factor κ-light-chain-enhancer of activated B cells and
phospho-c-Jun in HT-29 cells, L. rhamnosus L34 and L. casei
L39 decreased the production of C. difﬁcile-induced
granulocyte-macrophage colony-stimulating factor. Moreover,
L. acidophilus GP1B cell extract decreased transcriptional
levels of luxS, tcdA, tcdB and txeR genes of C. difﬁcile, thus
reducing virulence in vitro.248 In vivo, survival rates at 5 days
for mice that received C. difﬁcile and L. acidophilus GP1B cell
extract or L. acidophilus GP1B were reduced up to 80%.
Therefore, in vitro and in vivo investigations have showed that
lactobacilli presented antibacterial effects. Clinical studies of
lactobacilli showing efﬁcacy for treatment of diarrhoea have
been summarised in table 11.
Periodontal disease
Periodontal diseases can be divided into gingivitis and periodon-
titis.264 While the ﬁrst condition is characterised by
Table 14 Clinical studies of lactobacilli showing efficacy for treatment of various pathologies
Bacteria Dose Pathology Ref. (Design)
L. casei Shirota N/A Ventilator-associated pneumonia 291(prospective, randomised, open-label controlled study)
Synbiotic 2000:
P. pentosaceus 5–33:3
L. mesenteroides 32–77:1
L. paracasei 19
L. plantarum 2362
+
inulin, β-glucan, resistant
starch and pectin
1×1010 CFU (of each)
N/A
Severe acute pancreatitis 292(prospective, randomised, double-blind study)
Ecologic 641®:
L. acidophilus
L. casei
L. salivarius
Lact. Lactis
B. bifidum B. lactis
+
cornstarch and maltodextrins
1010 CFU (total)
N/A
Severe acute pancreatitis 293(multicentre randomised, double-blind, placebo-controlled
study)
Genefilus F19©:
L. paracasei subsp paracasei F19
+
high-fibre diet
12×109 CFU/2.5g
N/A
Symptomatic uncomplicated diverticular
disease
294(multicentre, randomised, controlled, open parallel-group
study)
L. GG > 5×1010 CFU Cirrhosis 295(open study)
Table 13 Clinical studies of lactobacilli showing efficacy for treatment of diabetes
Bacteria Dose Pathology Ref. (Design)
L. acidophilus,
L. casei,
L. rhamnosus,
L. bulgaricus,
B. breve,
B. longum,
St. thermophilus
+
fructo-oligosaccharide
2×109 CFU
7×109 CFU
1.5×109 CFU
2×108 CFU
2×1010 CFU
7×109 CFU
1.5×109 CFU
100 mg
Type-2 diabetes 282(randomised double-blind
placebo-controlled clinical study)
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inﬂammation of the gingiva,265 the second is a progressive
destructive disease which involves tooth supporting tissues such
as the alveolar bone.266 Periodontitis is mainly characterised by
the presence of Porphyromonas gingivalis, Treponema denticola,
Tannerella forsythia and Aggregatibacter actinomycetemcomitans
which colonise the subgingival sites escaping the host defense
system and eventually causing tissue damage.267 Among anti-
microbial and bacteriostatic agents, chlorhexidine is the gold
standard for treatment of periodontitis because of its broad-
spectrum antibacterial activity.268–270 However, a number of
side effects, such as brown teeth discolouration, salt taste per-
turbation, oral mucosal erosions and enhanced supragingival cal-
culus formation, have been reported and they have limited
chlorhexidine long-term use.271 Evidence has shown the effect-
iveness of lactobacilli in reducing gingival inﬂammation and the
number of cariogenic periodontopathogenic bacteria.272 Further
Table 15 Clinical studies reporting side effects associated with therapy with lactobacilli
Bacteria Effect/s Patient(s) clinical history Ref.
L. jensenii Endocarditis An immunocompetent 47-year-old man with mitral valve replacement treated with teicoplanin and
meropenem
302
L. paracasei Endocarditis A patient (18 years) with trisomy 21 treated with chloramphenicol 303
L. rhamnosus GG Bacteraemia Eleven patients with immunosuppression, prior prolonged hospitalisation and prior surgical
interventions treated with antimicrobials
317
L. acidophilus
L. bulgaricus
Bloodstream infections The maximum estimated incidence of bacteraemia during an 8-year period was 0.2% 322
L. rhamnosus Bacteraemia Sixteen nosocomial infections associated with immunosuppression (66%) and catheters (83%) 312
L. rhamnosus, L. curvatus
L. delbrueckii subsp
Lactis
L. paracasei
Bacteraemia Six cases of bacteraemia in hospitalised patients, five with a depressed immune status 306
L. rhamnosus Hepatic abscess and
bacteraemia
A 73 year-old woman with antecedent of diabetes mellitus treated with ampicillin plus gentamicin 316
L. rhamnosus Catheter-related bacteraemia A patient who underwent a single-lung transplant 308
L. rhamnosus Bacteraemia A 14-year-old girl with acute myeloid leukaemia, bacteraemia disappeared only after 13 months when
the cytostatic therapy was terminated
314
L. plantarum Bacteraemia A patient (43 years) with a subacute endocarditis due to an immunovasculitis and a bloodstream
infection
307
L. rhamnosus Septicaemia A 54-year-old woman with diabetes treated with amoxicillin 296
L. jensenii Septicaemia A 50-year-old woman with obstructive acute renal failure 297
L. paracasei Purpura fulminans associated
with liver abscess
N/A 323
L. acidophilus Liver abscess A 27-year-old man with a 6-month history of NOD2/CARD15-positive Crohn’s disease 324
L. casei Pneumonia and sepsis A patient with AIDS because of CD4 lymphocyte depletion 325
L. rhamnosus Septicaemia A patient with a graft in the inferior vena cava 298
L. gasseri Septic urinary infection A patient (66 years) developed severe urinary stasis due to a concrement in his right ureter, treated
with cefotaxime and amoxicillin
326
L. casei Bacteraemia A 75-year-old woman (a heavy dairy consumer)with severe thoracic pain due to dissection of the
aortic arch and ascending aorta and treated with amoxicillin
327
L. rhamnosus
Lcr35, ATCC53103
Meningitis Recurrent episodes
of Bacteraemia
A child (10 years ) undergoing allogeneic haematopoietic
stem cell transplantation and treated unsuccessfully with clindamycin
320
L. casei Bacteraemia An immunocompetent 66-year-old man with a history of fever of unknown origin 319
L. jensenii Bacteraemia and pyelonephritis A 59-year-old woman with progressed follicular lymphoma, diabetes mellitus type-2 and arterial
hypertension and kidney stone treated with antibiotics
309
L. jensenii Bacteraemia and endocarditis A 27-year-old woman with a 20-day history of fever and treated with penicillin and gentamicin 304
L. rhamnosus Catheter-related bloodstream
infections
A 38-year-old woman who underwent allogenic transplantation of haematopoietic stem cells from
cord blood for a large granular lymphocyte leukaemia and initially treated with chemotherapy
328
L. delbrueckii Pyelonephritis and Bacteraemia A 68-year-old woman with fever, chills, nausea, and vomiting and ureteral calculus with mild left
hydronephrosis treated with ampicillin
311
L. rhamnosus Sepsis A 24-year-old woman developed sepsis resulting from preoperative administration of probiotics
following an aortic valve replacement
301
L. rhamnosus GG Bacteraemia A 69-year-old man with stage IIIA mantle cell lymphoma and treated with probiotic-enriched yogurt
stopping
329
L. rhamnosus GG Bacteraemia An 11-month-old boy with fever and hypoxia and with a history of short bowel syndrome secondary
to resection of approximately 80% of the small intestine
310
L. acidophilus Sepsis A 69-year-old man with stage IIIA mantle cell lymphoma 315
L. rhamnosus GG Bacteraemia. A 36-week-gestation male infant with short gut syndrome secondary to congenital intestinal atresia
and volvulus
313
L. rhamnosus GG Bacteraemia. A 34-week-gestation male infant with gastroschisis 313
L. rhamnosus Bacteraemia A 43-year-old woman with ulcerative colitis 299
L. paracasei Endocarditis A 77-year-old man with a prostate cancer in remission, hiatal hernia, right hip prosthesis, mitral
insufficiency, hypertension, bipolar disorder, and daily consumer of probiotics
330
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studies have shown that lactobacilli reduced the prevalence of
moderate-to-severe gingival inﬂammation and improved plaque
index (clinically used to measure the state of oral
hygiene)273 274 as well as decreased the levels of the proinﬂam-
matory cytokines TNF-α, IL-8 and IL-1β.275 Saha and cowor-
kers investigated the role of selected lactobacilli in St. mutans
inhibition.276 L. reuteri strains NCIMB 701359, NCIMB
701089, NCIMB 702655 and NCIMB 702656 inhibited
St. mutans to non-detectable levels (<10 CFU/mL) suggesting
their use as therapeutic agents for caries and periodontal
disease. Moreover, L. fermentum NCIMB 5221 inhibited St.
mutans buffering the pH (4.18) of saliva containing this patho-
genic microbe and coaggregating with it also showing high
levels of sucrose consumption. Altogether, these studies suggest
that lactobacilli may improve oral health and reduce periodonto-
pathogenic bacteria. Clinical studies of lactobacilli showing efﬁ-
cacy for treatment of periodontal diseases have been
summarised in table 12.
Diabetes
Diabetes, a chronic metabolic disease, is characterised by ele-
vated blood glucose levels due to either insufﬁcient insulin pro-
duction by β-islet cells (type-1 diabetes) of the pancreas or
impaired insulin sensitivity of insulin target organs, that is,
adipose tissue, liver and muscle (type-2 diabetes or diabetes mel-
litus).277 In this context, inﬂammatory immune responses play a
crucial role in the progression of both types of disease.278–280
As for type-2 diabetes, it is generally treated with intestinal
α-glucosidase inhibitors.281 In this regard, Actinoplanes spp
have been shown to naturally produce potent α-glucosidase
inhibitor compounds including acarbose. Panwar and coworkers
ﬁrst isolated and extracted lactobacilli from human infant faecal
samples and evaluated their inhibitory activity against intestinal
maltase, sucrose, lactase and amylase, all enzymes involved in
hydrolysis of carbohydrates.281 This study showed that several
strains exert powerful inhibitory effects against the aforemen-
tioned enzymes and L. rhamnosus reduced glucose excursions in
rats during a carbohydrate challenge by inhibiting β-glucosidase
as well as α-glucosidase activities. Even if further studies are cer-
tainly needed, administration of lactobacilli may represent a
promising novel therapeutic tool for treatment of diabetes.
Clinical studies of lactobacilli showing efﬁcacy for treatment of
diabetes have been summarised in table 13.
Arthritis
Osteoarthritis, a chronic joint disease characterised by progressive
cartilage degeneration, subchondral bone sclerosis, synovial
inﬂammation and osteophyte formation,283 mainly affects weight-
bearing joints such as knees and hips. A chronic inﬂammatory
response occurs in synovial membranes with increased expression
of proinﬂammatory cytokines and mononuclear cell inﬁltration.284
Oral intake of skimmed milk fermented with L. delbrueckii subsp
bulgaricus OLL1073R-1 inhibits the development of
collagen-induced arthritis in mice. Moreover, a reduced secretion
of IFN-γ was also observed in these animals.285 Moreover, L. casei
suppresses experimental rheumatoid arthritis by downregulating
Th1-type inﬂammatory responses286 and its coadministration with
type-II collagen and glucosamine decreased the expression of
various proinﬂammatory cytokines and matrix metalloproteinases,
upregulating anti-inﬂammatory cytokines.287 The immunomodu-
lating activity of lactobacilli in rheumatoid arthritis was also con-
ﬁrmed by a trial on 45 adult men and women affected by this
pathology.288 Bacillus coagulans GBI-30, 6086, administered for
60 days in addition to standard antiarthritic medications, resulted
in an improvement in the Patient Pain Assessment score and statis-
tically signiﬁcant improvement in Pain Scale with respect to
placebo.
Other pathologies
Lactobacilli have found application for treatment of several
other pathologies. For instance, L. plantarum strain K21 that
inhibits lipid accumulation in 3T3-L1 preadipocytes, alleviated
body weight gain and epididymal fat mass accumulation,
reduced plasma leptin levels, decreased cholesterol and triglycer-
ide levels as well as mitigated liver damage in a mouse model of
diet-induced obesity.289 Antilipidemic effects of lactobacilli were
also evaluated along with memory-enhancing activity in aged
Fischer 344 rats.290 A probiotic mixture of L. plantarum
KY1032 and L. curvatus HY7601 was provided once a day for
8 weeks. A signiﬁcant inhibition of age-dependent increase in
blood triglycerides and a reduction in high-density lipoprotein
cholesterol was observed. Moreover, the mixture restored
age-reduced spontaneous alternation in the Y-maze task and age-
suppressed doublecortin and brain derived neurotrophic factor
expression. In addition, suppression of p16, p53 and
cyclooxygenase-2 expression, phosphorylation of protein
kinase B and mammalian target of rapamycin and activation of
nuclear factor κ-light-chain-enhancer of activated B cells
were observed, thus suggesting a therapeutic role of such
mixture in ameliorating age-dependent memory deﬁcit and
lipidemia in aged subjects. Clinical studies of lactobacilli
showing efﬁcacy for treatment of various pathologies have been
summarised in table 14.
SIDE EFFECTS OF LACTOBACILLI
The widespread clinical use of lactobacilli, even for pathologies
that are challenging to treat, has highlighted potential transloca-
tions or mutations and untoward effects such as sepsis,296–301
endocarditis,302–305 bacteraemia299 306–319 and even death.320
Evidence regarding lactobacilli side effect proﬁle has been sum-
marised in table 15.
CONCLUSIONS
The mammalian gut microbiome interacts with several physio-
logical systems within the host contributing to multiple bio-
logical processes. In vitro and in vivo investigations have shown
that prolonged probiotic administration induces qualitative and
quantitative modiﬁcations in complex, well-settled microbial
ecosystems through bacteriocin substrate competition and pos-
sibly other mechanisms that still need to be acknowledged.
Probiotics can modulate the GI tract microbial ecology exerting
immunomodulatory effects that are therapeutic at least for treat-
ment of speciﬁc pathologies.331 Our review takes into account
the available clinical and experimental evidence on the use of
lactobacilli in order to give an overview of their suitability to be
enclosed in well deﬁned updated therapeutic protocols for spe-
ciﬁc pathologies. A limited number of studies have already
tested the hypothesis that lactobacilli could be combined with
biﬁdobacteria or other nutrients, such as ﬁbres, in order to
enhance the bioavailability, mucosal adhesion and therapeutic
effectiveness of lactobacilli. Further studies are certainly war-
ranted to determine the most effective combinations for treat-
ment of individual pathologies. The claim that pools of
lactobacilli could better survive within the gut lumen and even
in the colon, and stably integrate within the pre-existing micro-
biome, has never been proved in terms of dose-effect and risk
of sepsis and bacteraemia. We do not have enough information
about the long-term genetic stability (with some exceptions such
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as L. paracasei subsp paracasei F19332 333), the antibiotic suscep-
tibility and translocation rate of L. strains.334–336 Therefore,
further investigations are required to ﬁll in this gap. We would
also like to point out the increasing interest in lactobacilli used
for industrial food fermentation which has reached a high
degree of sophistication that could be useful also for medical
applications.337 For example, various novel biological modiﬁca-
tions have been introduced such as the lysostaphin-expressing
gene to prevent growth of toxic shock syndrome toxin 1 produ-
cing strains of S. aureus.338
However, since data concerning the safety and genetic stabil-
ity of lactobacilli is still limited, toxicological studies evaluating
the effects of their genetic modiﬁcation on the homeostasis of
the host organism are still required. Ongoing research on the
human microbiome composition will likely yield new species of
the genus L. that might also have therapeutic applications for
speciﬁc pathologies.
Take home messages
▸ Experimental and clinical evidence supports lactobacilli
effectiveness for treatment of several pathological
conditions.
▸ Long-term consumption of lactobacilli induces qualitative
and quantitative modiﬁcations in the human gastrointestinal
microbial ecosystem.
▸ Pharmacological proﬁle of lactobacilli needs to be further
characterised in order to avoid translocation-related risks.
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